Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (16791)	5/16/2005 12:01:02 AM
From: Biomaven	Read Replies (1) \| Respond to of 52153

As they comment in the paper, applying this to beefing up Herceptin would seem to be an early possible application: In summary, by addressing the cooperative ability of certain mAbs to inhibit tumors, our study proposes Ab-induced down-regulation of growth factor receptors as a candidate mechanism of immunotherapy. Consistent with this notion, EGF-induced down-regulation of EGFR is considered a critical mechanism of signal attenuation (13). Further, the model we propose offers strategies to enhance the therapeutic efficacy of clinically approved Abs such as Herceptin and C225/Cetuximab. Along with testing the clinical implications of our findings, future studies will address possible interactions between the Fc portions of therapeutic mAbs and the caveolae/raft-associated endocytic machinery. But all very early still. Peter